Close Menu

NEW YORK (360Dx) — Shares of T2 Biosystems soared today on news that the US Food and Drug Administration granted Breakthrough Device Designation for its T2Resistance Panel.

In morning trading on the Nasdaq, the company's shares were up more than 25 percent at $4.73.

T2 Bio's panel can detect 13 resistance genes from both gram-positive and gram-negative pathogens and from a single patient blood sample without waiting for a blood culture.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.